Fredun Pharmaceuticals Limited has secured a significant credit rating upgrade from Infomerics Valuation and Rating Limited, marking a key milestone in the company's financial journey. The diversified pharmaceutical manufacturer, which operates across generics, cosmeceuticals, nutraceuticals, mobility and animal healthcare products, announced the upgrade on February 25, 2026.

Credit Rating Enhancement Details

Infomerics has upgraded the company's long-term bank facilities to IVR BBB+ with Stable Outlook from the previous IVR BBB with Stable Outlook rating. The rating agency simultaneously reaffirmed the short-term rating at IVR A2, demonstrating confidence in the company's near-term financial obligations management.

Performance Foundation for Upgrade

The rating upgrade reflects the company's strengthened operational performance and disciplined capital management demonstrated across FY24 and FY25. The upgraded IVR BBB+ rating indicates an enhanced degree of safety regarding timely servicing of financial obligations and demonstrates improving credit quality. The stable outlook signifies the rating agency's confidence in the company's ability to sustain its performance trajectory and maintain a balanced financial risk profile.

Notably, this follows a similar upgrade from Brickwork, which previously raised the company's bank facility credit rating from A3+ to A2, further validating the strengthening fundamentals.

Strategic Business Impact

This credit rating enhancement provides multiple strategic advantages for Fredun Pharmaceuticals as it continues expanding its global footprint. The upgrade strengthens banking confidence and institutional credibility while improving financial flexibility to support expansion initiatives. Additionally, it offers potential optimization of borrowing costs and enhanced positioning for future growth capital requirements.

As the company continues to expand its export presence across Africa, Southeast Asia, CIS countries and Latin America, the upgraded credit rating strengthens its financial flexibility to efficiently manage working capital and support strategic growth initiatives.

Management Commentary and Outlook

Commenting on the development, Managing Director Fredun Medhora stated, "This upgrade is encouraging for all of us at Fredun. It reflects the hard work of our team and the disciplined manner in which we are building the business. As we continue to grow across markets, our focus remains on strengthening the Company's foundation while pursuing larger opportunities responsibly."

Company Financial Performance

Fredun Pharmaceuticals reported strong financial results in FY25, demonstrating the operational strength that supported the rating upgrade:

The company maintains a diverse product portfolio spanning antihypertensives, antidiabetic medications, antiretroviral drugs, narcotics, dietary supplements, nutraceuticals, cosmeceuticals, and animal healthcare products. Its primary export markets include Africa, Southeast Asia, Commonwealth of Independent States countries, and Latin America, positioning it as a globally competitive pharmaceutical platform.

Fredun Pharmaceuticals Limited successfully conducted its Extra-Ordinary General Meeting (EOGM) on February 16, 2026, achieving unanimous shareholder approval for a key board appointment. The meeting was held through video conferencing at 09:00 a.m. IST, maintaining compliance with regulatory circulars issued by the Ministry of Corporate Affairs and Securities and Exchange Board of India.

Meeting Participation and Compliance

The EOGM demonstrated strong corporate governance practices with participation from multiple shareholder categories. Out of 8,645 total shareholders on the record date, 42 shareholders attended the meeting through video conferencing facilities.

The company maintained strict adherence to regulatory requirements, with the book closure period running from Tuesday, February 10, 2026, to Monday, February 16, 2026. Shareholders holding shares as of February 9, 2026, were entitled to participate in the voting process.

E-Voting Process and Results

The electronic voting was conducted through National Securities Depositories Ltd (NSDL) platform, with remote e-voting available from February 13, 2026, at 09:00 a.m. to February 15, 2026, at 05:00 p.m. The sole agenda item was a special resolution for the appointment of Mrs. Pooja Narendra Sanghavi (DIN: 11387388) as Non-Executive Independent Director.

Category-wise Voting Breakdown

The voting results demonstrated strong support across all shareholder categories, with the resolution receiving unanimous approval.

Scrutinizer Report and Regulatory Compliance

Ms. Kala Agarwal, Practicing Company Secretary (Membership No. 5976 & Certificate of Practice No. 5356), served as the appointed scrutinizer for the e-voting process. The scrutinizer confirmed that all voting procedures were conducted in accordance with Section 108 of the Companies Act, 2013, and Rule 20 of the Companies (Management and Administration) Rules, 2014.

The resolution was declared "PASSED" with the requisite majority, and the appointment of Mrs. Pooja Narendra Sanghavi as Non-Executive Independent Director was deemed effective from the date of the EOGM. The company has fulfilled its disclosure obligations under Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring transparency in the voting process and results.